JNCE: Short Term Momentum Trade 短期动力交易股:JNCE

Jounce Therapeutics, Inc., (JNCE 7.39) a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.

"Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX -1811 program. Under the terms of the agreement, Gilead will make a $85 million upfront payment to, and a $35 million equity investment at a premium in, Jounce upon closing. In addition, Jounce may receive up to an additional $685 million in future clinical, regulatory and commercial milestone payments. Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments."  ---Globenewswire

This is huge news for JNCE.  Jounce's income for last year is only around $22 millions, the $85 millions up front payment, $35 millions investment and possible $685 millions payment from GILD suddenly opened up tremendous valuation increases for JNCE. Just the $85 million up front payment is already 4 times JNCE's 1 year income, not to mention the additional $35 millions and the $685 millions future potential. Longer term, doubling from here is not far fetched. JNCE is a good short term momentum trade. Short term target 10.

Other positives for JNCE:

1. JNCE gapped up today from a 1 month narrow range trading range with 198 times average volume. It has turned from a downtrend to a up trend with a lot of momentum. Its initial resistance is $8 then $10. If 10 is broken, a 2 1/2 year base will be formed and price should be able to accelerate a lot higher.

2. Jounce only has only 30 millions share flow and 7% shorts. It can easily get bid up.

3. Institutions own 76% of shares, plenty of institution sponsorship.

4. No long term debts and current ratio is a strong 8. 

5. Jounce Book Value is $3.74.

临床阶段免疫疗法公司Jounce Therapeutics，Inc.（JNCE 7.39）是开发用于癌症治疗的疗法的公司。

“ Gilead Sciences，Inc.（Nasdaq：GILD）今天宣布与临床阶段公司Jounce Therapeutics，Inc.（Nasdaq：JNCE）达成协议，Junce Therapeutics，Inc.（Nasdaq：JNCE）是一家临床阶段公司，致力于发现和开发新型癌症免疫疗法和预测性生物标记，并独家授权JTX -1811计划。根据协议条款，吉利德将在完成交易后向Jounce支付8500万美元的预付款，以及3500万美元的溢价股本投资，此外，Jounce可能还会再获得最高6.85亿美元的收益。这是未来的临床，监管和商业里程碑付款。根据全球销售情况，Jounce还将有资格获得从高个位数到十几的特许权收入，但会进行某些调整。” --- Globenewswire

对于JNCE而言，这是一个重大新闻。 Jounce去年的收入仅为2200万美元左右，GILD前期付款为8500万美元，投资为3500万美元，及可能支付的6.85亿美元突然为JNCE带来了巨大的估值增长。仅8500万美元的预付款已经是JNCE一年收入的4倍，更不用说额外的3500万美元和6.85亿美元的未来潜力。给它多些时间，股价再升一倍也不为过。 JNCE是很好的短期动力交易股票。短期目标位10美元。

JNCE的其他优势：

1. JNCE今天从1个月的窄幅交易区间中跳空上升，交易量是平均交易量的198倍。它已经从下降趋势转变为上升趋势，并且上升势头强劲。它的初始阻力是8美元，然后是10美元。如果向上突破10美元，则将形成2 1/2年的坚固底部，价格应该能够加速上升更高。

2. Jounce只有3,000万股流通股票，卖空率为7％。股价可以很容易地被推高。

3.机构拥有76％的股份，机构赞助很多。

4.无长期债务，流动比率位强劲的8。

5.账面价值为3.74美元。